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Objectives: Detection of rarer carbapenemases is challenging, as it requires molecular assays with comprehen-
sive coverage or the use of phenotypic methods for the detection of carbapenemase activity. We describe a new
class A carbapenemase, FRI-2, in an Enterobacter cloacae complex isolate following implementation of an in-
housemultiplex PCR for the detection of ‘rare’ class A carbapenemases.
Methods:MICs were determined by agar dilution. A carbapenem-resistant E. cloacae complex isolate was tested
by PCR for the class A carbapenemases blaKPC, blaFRI, blaIMI, blaGES and blaSME. Carbapenemase activity was as-
sessed using Carba NP and the carbapenem inactivation method. Whole genome and plasmid analyses of the
clinical isolate and the FRI-2 transformant were performed byWGS, respectively. Typing was carried out by PFGE.
Results: The E. cloacae complex isolate showed resistance to imipenem (MIC"16mg/L), meropenem
(MIC"8mg/L) and ertapenem (MIC"8mg/L), but remained susceptible to piperacillin/tazobactam
(MIC"8mg/L). Carbapenemase activity was conﬁrmed in the isolate by both phenotypic methods. A blaFRI-1-like
gene was detected by PCR and analysis of WGS data of the clinical isolate identiﬁed an ORF of 885bp, which
showed 97%nucleotide identity with blaFRI-1 andwas named blaFRI-2. WGS of the transformant indicated blaFRI-2
was located on a 108kb IncF/IncR plasmid. The FRI-2-positive E. cloacae complex isolate belonged to a novel ST
(ST829).
Conclusions: The possible circulation of rarer carbapenemases in clinical settings highlights the role of pheno-
typic tests to detect carbapenemase activity whenmolecular assays are negative for the ‘big 5’ carbapenemase
families.
Introduction
In Enterobacteriaceae, carbapenem resistance mediated by car-
bapenemases is mostly attributed to the interspecies dissemin-
ation of KPC, OXA-48-like, NDM, VIM and IMP alleles. Although the
dispersion of the ‘big 5’ carbapenemases has been reportedworld-
wide, some carbapenemases, such as blaSME or blaSPM, are still spe-
cies- or, largely, country-speciﬁc.1,2
Class A carbapenemases other than KPC include the closely
related NMC-A and IMI, SME, GES, BIC-1, SFC-1 and BKC-1.3 The de-
tection of these carbapenemases poses a problem in terms of in-
fection prevention and control as most commercial and in-house
molecular assays have limited coverage and focus on the detec-
tion of the ‘big 5’ families. Moreover, due to the rarity of these other
carbapenemases and their potential susceptibility to cephalo-
sporins, phenotypic tests could be misinterpreted as false-
positives if further extended molecular characterization is not
undertaken.4
Dortet et al.5 recently identiﬁed a novel class A carbapenemase,
FRI-1, in an isolate of Enterobacter cloacae in a patient in France.
FRI-1 shares 53% and 42% identity with SFC-1 and BKC-1, respect-
ively, and is related to a subgroup including SME-1, IMI-1 and
NMC-A, with identity ranging from54% to 56%.
PHE’s Antimicrobial Resistance and Healthcare Associated
Infections (AMRHAI) Reference Unit has recently implemented
an in-house multiplex PCR for the detection of the ‘rare’ class A
carbapenemases FRI, IMI, GES and SME. During screening of
clinical isolates sent to the AMRHAI Reference Unit for investi-
gation of carbapenem resistance, we identiﬁed a variant of
FRI-1 in an E. cloacae complex strain, subsequently named
FRI-2.
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Materials and methods
An E. cloacae complex isolate 587 was submitted to PHE’s AMRHAI
Reference Unit in June 2016 for investigation of carbapenem resistance.
This isolatewas recovered froma patientwho attendedanoutpatient clinic
at the University Hospital of South Manchester (UK) and as part of routine
assessment prior to a coronary artery bypass graft underwent rectal
screening for carbapenemase-producing Enterobacteriaceae (CPE). Rectal
screening for CPE using culture is routine for patients at higher risk of CPE
carriage (including those admitted to hospitals in Greater Manchester in the
previous year).6 The patient had been admitted for cardiac problems in two
hospitals in England including the referring hospital in the year before de-
tection. The patient had no recent history of antibiotic administration or
travel abroad. No previous CPE had been isolated from this patient, al-
though there had beenno previous rectal screening for CPE.
MICs were determined by agar dilution against AMRHAI’s standard
Gram-negative antibiotic panel, which includes imipenem (+EDTA for MBL
detection), ertapenem and meropenem (+avibactam for class A carbape-
nemases detection), and interpreted using EUCAST criteria.7
Carbapenemase genes, including various class A carbapenemases
(blaKPC, blaFRI, blaIMI, blaGES, blaSME) were sought using in-house multiplex
PCRs8 with the following primers for the detection of genes encoding FRI-1
(FRI-1 For: 50-AGG TGA ATT GGC GTC TGT CC-30 and FRI-1 Rev: 50-GGG GGC
GGA TAG GTG TTT AT-30), IMI (IMI-for: 50-CTA CGC TTT AGA CAC TGG CTC-30
and IMI-rev: 50-TTG GTA CGC TAG CAC GAA TA-30), GES (GES-F: 50-TTT CTA
GCA TCG GGA CAC AT-30 andGES-R: 50-ACAGCG TAA TCT CTC TCC TG-30) and
SME (SME-F: 50-AAC GGC TTC ATT TTT GTT TAG-30 and SME-R: 50-GCT TCC
GCAATAGTT TTA TCA-30) enzymes.
Evidence of carbapenemase activity was sought using RapidecV
R
Carba
NP (bioMe´rieux SA, Marcy-l’Etoile, France) and the carbapenem inactivation
method (CIM).9
Electroporation was performed using Escherichia coli Alpha-Select re-
cipient cells (Bioline, London, UK). Transformants were selected on LB agar
(Oxoid Ltd, Basingstoke, UK) containing 100mg/L ampicillin (Sigma–
Aldrich, Gillingham, Dorset, UK) andwere screened for blaFRI-1 by PCR before
WGS.
WGSwas performed on both the clinical isolate and FRI-2 transformant
using a Hiseq sequencer (Illumina) and the resulting data were analysed
using an in-house bioinformatics pipeline; resistance genes were identiﬁed
bymapping reads against a library curated in-house frompublically access-
ible databases.10 Transformant reads were assembled into contigs using
SPAdes 3.5.0 (http://bioinf.spbau.ru/spades), with K-mer values of 21, 33,
55 and 77. Plasmid contigs were extracted from the known E. coli host gen-
ome and gaps were closed by PCR and subsequent Sanger sequencing.
Plasmid replicon types were determined using PlasmidFinder11 on the
Center for Genomic Epidemiology platform (https://cge.cbs.dtu.dk/services/
). Genes were inferred and annotated using PROKKA12 and BLAST. ST was
determined in silico (https://pubmlst.org/ecloacae/).13
Typingwas carried out by PFGE of XbaI-digested genomicDNA.
Nucleotide sequence accession numbers
The nucleotide sequence data have been submitted to the GenBank nu-
cleotide database under accession no. KX620467 for blaFRI-2 and KX912253
for the plasmid pJF-587.
Results and discussion
Resistance to carbapenems in Enterobacter spp. isolates is encoun-
tered frequently in the UK, but is mainly associated with a
combination of several mechanisms including production of ESBL,
increased efﬂux, porin alteration and/or overproduction of the
intrinsic AmpC enzyme,14,15 hence the difﬁculty in relating
carbapenem resistance with carbapenemase production.
Between 2004 and the end of December 2016, 3666 Enterobacter
spp. isolates had been received in AMRHAI for investigation of car-
bapenem resistance with 1059 (28.9%) isolates conﬁrmed as car-
bapenemase producers [KPC (n"349), OXA-48-like (n"356),
NDM (n"198), VIM (n"79), IMP (n"38), IMI (n"22), GES-5
(n"6) and the one E. cloacae producing FRI-2 reported here;
10 isolates co-produced two carbapenemases; K. L. Hopkins and
N.Woodford, AMRHAI, unpublisheddata].
The E. cloacae complex isolate was resistant to
imipenem (MIC"16mg/L), meropenem (MIC"8mg/L), erta-
penem (MIC"8mg/L) and aztreonam (MIC"32mg/L), but re-
mained susceptible to the cephalosporins (cefotaxime, 1mg/L;
ceftazidime, 0.5mg/L; and cefepime, 0.125mg/L) and to non-
b-lactam antibiotics including colistin (MIC 0.5mg/L), amino-
glycosides (gentamicin, 0.25mg/L; tobramycin, 0.5mg/L;
and amikacin, 1mg/L) and ciproﬂoxacin (MIC 0.125mg/L)
(Table 1). Carbapenem resistance of the isolate with relative
susceptibility to the cephalosporins and synergy observed be-
tween meropenem (MIC"8mg/L) and meropenem/avibactam
(MIC"0.03mg/L; the concentration of avibactam is ﬁxed at
4mg/L) suggested production of a class A or D carbapenemase.
The isolate remained susceptible to piperacillin/tazobactam
(MIC"8mg/L) and temocillin (MIC"4mg/L), and KPC and OXA-
48-like carbapenemases were excluded by PCR; however, Carba
NP and CIM conﬁrmed carbapenemase activity in the isolate.
An ampicillin-resistant transformant was resistant to aztreo-
nam (MIC"16mg/L) and showed reduced susceptibility to erta-
penem (MIC"0.25mg/L), meropenem (MIC"0.125mg/L) and
imipenem (MIC"4mg/L) compared with the carbapenem MICs
for the recipient strain (Table 1).
A blaFRI-1-like gene was detected by in-house multiplex PCR,
and was conﬁrmed by Sanger sequencing of the amplicon.
Subsequent analysis of WGS data of the E. cloacae complex iso-
late identiﬁed an ORF of 885 bp, which showed 97% nucleotide
identity with blaFRI-1. The newly named blaFRI-2 was predicted to
encode a 294 amino acid protein, which shares 275/294 (94%)
amino acid identity with FRI-1 (Figure 1a). The other antibiotic
resistance genes detected by WGS were blaACT-2, encoding a
chromosomal AmpC enzyme, fosA, and a mutation in gyrA at
position 83 (S!T). WGS of the transformant indicated blaFRI-2
was located on a 108 kb IncF/IncR plasmid, which did not share
signiﬁcant homology with any plasmid sequences in public
databases. The LysR family regulator (FRI-R) was present down-
stream of blaFRI-2 and shared 95.8% identity with FRI-R
described downstream of blaFRI-1; the ISEc8 element described
upstream of blaFRI-1 was absent.
5 Downstream of blaFRI-2, a
MerR family transcriptional regulator was identiﬁed where
ISEc14 was previously characterized near blaFRI-1 (Figure 1b).
One hundred and nineteen ORFs were identiﬁed on the 108 kb
plasmid with 69 ORFs showing no similarity with published se-
quences. The remaining ORFs encoded for genes involved in
plasmid conjugation and partitioning; no other resistance genes
or any virulence genes were encoded on the plasmid.
The G!C content for both blaFRI-2 and blaFRI-1 was similar
(39%); however, the plasmid pJF-587 bearing blaFRI-2 had a G!C
content of 52% suggesting horizontal acquisition of the gene.
The ﬁrst reported FRI-1-producing E. cloacae complex strain
was recovered from a urine sample of a patient hospitalized in
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France and who had travelled to Switzerland.5 The UK patient had
no travel history, and the only risk factor potentially associated
with acquiring the FRI-2-positive E. cloacae complex strain was
previous hospitalization in two hospitals in North West England.
PFGE typing of the E. cloacae failed due to DNA degradation so no
comparison with E. cloacae isolates from either of the hospitals at-
tended by the patient could be performed. TheWGS data analysis
showed that the FRI-2-positive E. cloacae isolate belonged to a
novel ST (ST829).
To the best of our knowledge, this is only the second report
globally of a FRI family carbapenemase. FRI-2 has substantial
sequence divergence from FRI-1 (6% amino acid differences),
andmay therefore represent a distinct gene ‘escape’ event from
an unidentiﬁed source species. Other class A carbapenemases
previously identiﬁed in the Enterobacter genus include KPC and
rarer carbapenemases, such as IMI and GES. The identiﬁcation of
blaIMI in E. coli and Klebsiella variicola demonstrates that despite
the rare isolation of such carbapenemases, they have the poten-
tial to transfer within and between species.16,17 The presence of
ISs and the location of FRI-2 on a plasmid highlight this poten-
tial. The identiﬁcation of FRI-2 in a clinical setting in the UK dem-
onstrates the role of phenotypic tests to detect carbapenemase
activity. When molecular assays are negative for the ‘big 5’ car-
bapenemase families, microbiologists should consider the possi-
bility of other carbapenemase types that are currently rare, but
have the potential to become more signiﬁcant public health
problems.
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Table 1. MICs of different antibiotics for E. cloacae, E. coli Alpha-Select transformed with pJF-587 and E. coli Alpha-Select
Antibiotic
MIC (mg/L)
E. cloacae pJF-587 E. coli Alpha-Select (FRI-2) E. coli Alpha-Select
Ertapenem 8 0.25 0.125
Imipenem 16 4 0.25
Imipenem/EDTA 8 2 0.125
Meropenem 8 0.125 0.060
Meropenem/avibactam (4mg/L) 0.03 0.015 0.015
Cefotaxime 1 0.125 0.125
Cefotaxime/clavulanate 0.25 0.060 0.060
Ceftazidime 0.5 0.25 0.125
Ceftazidime/clavulanate 0.25 0.125 0.125
Ceftazidime/avibactam 0.25 0.125 0.25
Cefepime 0.125 0.125 0.125
Aztreonam 32 16 0.125
Temocillin 4 8 4
Piperacillin/tazobactam 8 1.0 1.0
Ciproﬂoxacin 0.125 0.125 0.125
Gentamicin 0.25 0.25 0.25
Tobramycin 0.5 0.25 0.25
Amikacin 1 1 0.5
Tigecycline 0.5 0.250 0.250
Colistin 0.5 0.5 0.5
Carba NP ! NT NT
CIM ! NT NT
NT, not tested.
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